Coherus BioSciences (CHRS) Misses Q1 EPS by 205c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $0.85 --0%
Revenue Growth %: +37.8%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
KEEL, SENEA, XFOR, More
Revenue Growth %: +37.8%
Financial Fact:
Gain from sale of office premises: 0
Today's EPS Names:
KEEL, SENEA, XFOR, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q1 EPS of ($0.35), $2.05 worse than the analyst estimate of $1.70. Revenue for the quarter came in at $7.6 million versus the consensus estimate of $54.36 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Icahn Enterprises L.P. (INGR) Tops Q3 EPS by 12c ; Offers Guidance
- Pyxis Oncology, Inc. (PYXS) Tops Q3 EPS by 4c
- Entrada Therapeutics, Inc. (TRDA) Tops Q3 EPS by 7c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
